unit state go sg websit
soft growth profil could boost major acquisit
upsid tp
nc chang
despit diversif vaccin consum inject new
drug growth profil remain sector averag due tail
product could help boost profil drive
rerat bm remain favourit potenti candid believ
target price adequ reflect pfizer lower growth compound-annual-growth-rate
vs sector
robust new product perform inherit portfolio continu weigh
overal result slightli outperform pharma sector last
three month due signific success product ibranc
cancer benefit us tax reform point decreas tax rate adjust
incom challeng remain need boost growth tail portfolio
contribut fade time due gradual eros drug
new product ramp nice howev believ unlik
suffici drive growth line phama peer despit cost-contain initi
potenti still good way strengthen growth profil pipelin
continu believ activ could help improv pifzer growth profil creat
valu sharehold worth rememb group enjoy strong track record
larg transact last one wyeth potenti link-up bm remain
attract view given immune-oncolog portfolio despit long-term patent
expiri cardio cancer assum premium cash offer
share total consider cost synergi estim
transact would accret earn creat valu net debt/ebitda
would jump would back thank strong cash flow gener
possibl dispos consum arm potenti valu would help option still
evalu accord manag scenario link-up bm
impli pro forma valuat show discount vs pharma given improv
profil believ potenti rerat
hold reiter dont believ new product cancer inflamm
enough re-energis top line low single-digit growth vs sector
group trade discount peer price-to-earnings below-sector growth
potenti impact ebit
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
outperform us pharma sector past month
past three month alon
longer break-up stori although noth rule
view big challeng compani size high contribut matur portfolio
sale come highli profit cash cow area tail product
enter slow inexor declin fortun know innov product
ibranc see breast cancer novarti section find right partner
eliqui new oral anticoagul area bm see bayer section
stand-alone basi compani alreadi rel diversifi sale
gener consum vaccin steril inject product via
hospira busi acquir growth prospect remain weaker peer
due patent expiri product lyrica enbrel ra combin
sale presenc tail product account total sale
current declin low single-digit pace
pfizer ep growth remain peer due soft top line
despit cost-contain measur success new product ibranc set becom
super-blockbust improv oper margin share
buy-back programm assum per year
estim close consensu short term slightli bullish
margin bit conserv beyond take new product
early-stag pipelin
valuat discount still justifi view
target price tp deriv averag sum-of-th part sotp valuat
dcf use wacc long-term adjust ebita margin
perpetu growth slightli adjust tp reflect lower sector comparison
multipl lower long-term oper profit
part
averag pharma premium innov
vaccin consum discount matur portfolio
sotp estim differ oper margin subdivis see bar chart
appli premium larg pharma sector ev/ebita multipl pharma
vaccin consum divis discount matur portfolio
sum part
number share
valuat show higher number innov health sub-divis product
longer patent life despit lower margin vs essenti health portfolio
estim note consum busi could valu estim
event acquisit third parti view base recent transact
estim ebita margin sub-divis
sotp breakdown sub-divis per share base
share current trade discount peer forward price-to-earnings
base consensu slightli averag discount tp discount would
price-to-earnings
bull/bear approach show rather balanc profil group
show strong growth good visibl long durat establish busi
good vaccin consum inject declin tail portfolio seem
control limit contribut pipelin upsid
downsid well
bull/bear scenario impact sale
bull/bear scenario impact ebita
bull/bear scenario impact sale categori
bull/bear scenario impact ebita categori
see littl crucial news although new bavencio result
interest next import result lung avail
market alreadi crowd life-cycl manag continu notabl xeljanz
tremelimumab partner azn
osteoarthr hip knee
tremelimumab partner azn
phase result head head line
major bm still attract target view
long tradit major activ legendari move involv
wyeth pharmacia warner lambert compani
could also interest mid-siz deal one struck last year mediv
cancer although cant see much valu creation within next five year
alreadi state last year view bm potenti candid fit well
portfolio think could bring presenc immune-oncolog area
despit bmss mix result opdivo lung cancer trial far posit
forefront innov area io
moreov continu believ agreement avelumab merck kgaa
manag decid return right origin german group
present pharma account sale could easili find anoth
pharma compani interest leapfrog competitor highli competit
promis market potenti includ indic see therapeut area
section io race drug phase alreadi market small indic
merkel cell carcinoma rare highli aggress skin cancer urotheli carcinoma
combin sale bristol-my squibb
potenti accret valu creativ transact although without
assum premium cash-per-share offer total consider
cost synergi calcul theoret transact would ep
accret creat valu beyond basi net debt/ebitda
jump although would expect fall back would expect
strong cash flow gener consum busi dispos newco also boast
stronger growth profil approach sector averag
estim impact sharehold potenti deal bm
sale bm
net incom bm
debt
net impact net profit
earn accret dilut
fy othersbaraclud yervoy orencia sprycel eliqui opdivo innovativesxeljanzibrancevaccinesconsumerlyrica ihenbrelinject tail portfolio
think potenti transact would need high cost synergi gener strong valu
creation sharehold see even premium
sensit analysi roce premium paid cost synergi
theoret newco top-lin growth profil improv nice short term
bottom line would like show mid- high single-digit improv
view oper margin would also improv slightli thank cost synergi bmss
margin much lower pfizer howev given gener risk profil bm beyond
sprycel cancer eliqui cardiolog expect lower contribut long term
newco growth margin profil
estim pfizer gear net debt/ebitda would surg net
debt first year assum transact due strong cash flow
gener would expect return although still
net debt could use dispos consum busi reduc level
valuat potenti newco would impli discount pharma sector
p/e assum discount pharma sector stand-
alon tp impli valuat newco come estim
suggest despit execut risk size deal move would like
accret valu creativ sharehold would therefor drive rerat
impli valuat theoret newco assum discount vs pharma sector multipl
potenti dispos consum divis financ innov reduc
leverag event major transact
manag reiter still explor potenti strateg altern
consum divis sale reach decis year retain
busi full dispos potenti acquir look busi gsk reckitt
short list accord bloomberg although specifi compani
believ cash rais potenti dispos could use financ anoth big mid-siz
appetit long-dur asset area good visibl due patent expiri risk
strong brand recognit strong pfizer main brand pain advil multi-
vitamin centrum also respiratori dietari supplement howev challeng
would switch long-dur busi riski volatil biotech-
like portfolio inde decid acquir biotech-lik asset
given recent transact multipl sector reckitt/mead johnson believ sale
could fetch sale
bull/bear scenario potenti impact ebit
impact
pressur biosimilar pa
stronger success twice penetr
slightli lower penetr
price pressur
approv
gradual penetr variou
approv
product sold
net earn attribut sharehold
equival
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
product sold
net earn attribut sharehold
equival
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
share basic year end/outstand
share price average hist yr current
america
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
target price averag sotp averag ev/ebita pharma multipl appli estim ebita four
subdivis discount tail portfolio premium innov product premium vaccin
consum reflect visibl growth profil dcf valuat lt growth lt ebita margin
main risk faster eros establish product high single-digit impact ebit stronger biosimilar impact
enbrel low single-digit impact tougher ibranc competit landscap breast cancer low single-digit impact upsid risk greater
success ibranc double-digit impact
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
